Industry Reports

Q4 2018
The cell and gene therapy community gathered recently in La Jolla at the annual “Meeting on the Mesa” of the Alliance for Regenerative Medicine to review the state of the industry. The mood was ebullient as attendees celebrated the emergence of the industry from “R&D/developmental puberty” into commercial adulthood. The clear consensus was that cell/gene therapy, benefiting from substantial R&D and development efforts over the last two decades, has come of age in its ability to provide trans-formative new treatments for patients.
Q4 2018
Within the Behavioral Healthcare Services industry, companies that offered child and youth-oriented services accounted for 24.3% or 17 of the announced or closed mergers and acquisitions year-to-date. Activity in this segment has largely been driven by the national rise in children with autism (a 15.0% increase from 2016 to 2018, according to Autism Speaks) and the ongoing battle against opioid abuse (which is most prevalent among young adults ages 18-to-25 years old).
Q4 2018
The Healthcare Staffing sector continues to benefit from an increasingly tight labor market due to strong economic conditions coupled with increased health care utilization as the US population agencies and a wave of retiring Baby Boomer healthcare practitioners. The gap between openings and hires in healthcare has been widening rapidly since 2014 reaching a projected labor gap in July of approximately 536,000 healthcare professionals according to the Bureau of Labor Statistics (BLS).
Q3 2018
We are pleased to present our Q3 2018 Medical Device Outsourcing Industry Markets, Mergers & Acquisitions Update.  By 2023, the Drug-Device Combination market value will reach $29.8 billion, increasing at a 13.8% compound annual growth rate from 2018 to 2023, a much faster growth than that of the overall Medical Device industry.  Drug-device combination products include any combination of a drug or biologic with a medical device.  Examples of drug-device combination products include prefilled drug delivery systems, drug-eluding stents, wearable injectors, and insulin deli
Q3 2018
Contract Research Organizations (CROs) remain the most targeted segment in the Pharmaceutical Outsourcing industry, accounting for 45.2% of deals to-date in 2018 compared to 38.3% in all of 2017. Buyers have sought to cut clinical trial times and reduce spending through these strategic acquisitions.  In August, Capstone Headwaters advised Gibraltar Laboratories on its sale to Sotera Health LLC, a portfolio company of Warburg Pincus and GTCR. 
Q3 2018
Behavioral healthcare services are in high demand as organizations address the rising need for treating alcoholism, opioid and other drugs addictions, eating disorders, and mental illnesses.  Following the 27.6% year-over-year increase in merger and acquisition (M&A) activity in 2017, acquisitions continue at a rapid pace as leading industry players and private equity firms acquire to gain market dominance or to capitalize on the strength of the industry.  
Q3 2018
Merger and acquisition (M&A) volume in the industry has been precisely on pace with last spring, with 23 deals announced or closed year-to-date in both 2018 and 2017. A closer look at the numbers reveals that two verticals in particular, school-based therapy and autism treatment, are seeing intensifying M&A activity. Through Q2 2018 10 deals have been announced or closed in these verticals compared to six deals through the same period in 2017.
Q2 2018
The Healthcare Staffing industry has seen robust growth in the midst of one of the longest economic expansions in US history. The US temporary staffing market for healthcare occupations has grown from $10.1 billion in 2013 to a record $15.9 billion last year, a 57% jump according to Staffing Industry Analysts.  The national unemployment rate hovered at 17-year low of 4.1% for six consecutive months, before edging down to 3.9% in April and 3.8% in May (US Bureau of Labor Statistics).  
Q2 2018
Buyers continue to target Healthcare Information Technology (HCIT) companies as they seek to modernize and adapt to the evolving landscape of the US healthcare system.  One key regulatory change that is impacting the Healthcare industry and sparking HCIT merger and acquisition (M&A) activity is the shift from the current volume-based (fee for service) payment model to a value-based payment model.  

Pages